Skip to main content

Edgewise Therapeutics, Inc.

EWTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001710072

In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Edgewise Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
2 filings
2 insiders, $8.67M in total
Insiders trading
2
Net value
−$8.67M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Edgewise Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Edgewise Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Nofi MichaelChief Financial Officer–Aug 17, 20262
Donovan Joanne M.CMO4,367Aug 17, 20265
Russell Alan JChief Scientific Officer24,555Aug 17, 20263
Moore John RGeneral Counsel10,214Aug 17, 20261
Derakhshan BehradChief Business Officer23,645Aug 17, 20261
Koch KevinPresident and CEO52,488Aug 14, 20261
Root Jonathan DDirector0IndirectJul 17, 20261
Fox Jonathan CDirector24,833Jul 1, 20266
Thompson Peter A.Director, 10% Owner443,792IndirectJun 17, 20261
Morris ArleneDirector–Jun 17, 20261
Brege LauraDirector–Jun 17, 20261
Edris BadreddinDirector19,820Jun 16, 20262
Martin Christopher NathanDirector–Jun 16, 20262
Carruthers R MichaelChief Financial Officer86,162Aug 14, 20250
Blaustein RobertChief Development Officer–Aug 14, 20250
OrbiMed Advisors LLCDirector, 10% Owner443,792IndirectApr 4, 20250
OrbiMed Capital GP VI LLCDirector, 10% Owner443,792IndirectApr 4, 20250
OrbiMed Genesis GP LLCDirector, 10% Owner443,792IndirectApr 4, 20250
Semigran MarcChief Development Officer6,716Dec 27, 20240
Novo Holdings A/S10% Owner6,071,703Sep 16, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 14, 2026 (view filing)4:52 PM ETAug 122 daysKoch KevinPresident and CEOSSale−18.0K$43.68−$785.0K−25.5%52.5K after3 lots
Jul 2, 2026 (view filing)5:21 PM ETJul 11 dayRussell Alan JChief Scientific OfficerSSale−200.0K$39.41−$7.88M−89.1%24.6K after2 lots10b5-1
May 5, 2026 (view filing)May 4-51 dayDonovan Joanne M.CMOSSale−55.2K$37.88−$2.09M−92.7%4.37K after2 lots
Apr 2, 2026 (view filing)Apr 11 dayDonovan Joanne M.CMOSSale−28.7K$32.31−$926.1K−74.9%9.60K after10b5-1
Mar 31, 2026 (view filing)Mar 31Same dayDonovan Joanne M.CMOSSale−21.3K$32.12−$685.4K−69.0%9.60K after10b5-1
Mar 30, 2026 (view filing)Mar 273 daysDonovan Joanne M.CMOSSale−16.4K$30.98−$506.8K−63.0%9.60K after2 lots10b5-1
Jan 23, 2026 (view filing)1:34 PM ETJan 212 daysEdris BadreddinDirectorSSale−115.5K$29.44−$3.40M−85.4%19.8K after5 lots10b5-1
Nov 13, 2025 (view filing)6:06 PM ETNov 121 dayRussell Alan JChief Scientific OfficerSSale−100.0K$21.12−$2.11M−81.0%23.4K after
Nov 13, 2025 (view filing)Nov 112 daysFox Jonathan CDirectorPPurchase+10.7K$18.64+$199.4K+82.3%23.7K after
Aug 28, 2025 (view filing)4:55 PM ETAug 262 daysRussell Alan JChief Scientific OfficerSSale−100.0K$14.60−$1.46M−81.0%23.4K after
Aug 14, 2025 (view filing)Aug 122 daysMoore John RGeneral CounselSSale−2.10K$13.39−$28.1K−17.0%10.2K after
Aug 14, 2025 (view filing)Aug 122 daysDerakhshan BehradChief Business OfficerSSale−2.49K$13.39−$33.4K−9.5%23.6K after
Aug 14, 2025 (view filing)Aug 122 daysCarruthers R MichaelChief Financial OfficerSSale−1.43K$13.39−$19.1K−1.6%86.2K after
Aug 14, 2025 (view filing)Aug 122 daysRussell Alan JChief Scientific OfficerSSale−1.91K$13.39−$25.5K−7.5%23.4K after
Aug 14, 2025 (view filing)Aug 122 daysKoch KevinPresident and CEOSSale−7.97K$13.39−$106.7K−20.7%30.6K after
Aug 14, 2025 (view filing)Aug 122 daysDonovan Joanne M.CMOSSale−2.86K$13.39−$38.3K−10.1%25.4K after
May 7, 2025 (view filing)May 25 daysLateRussell Alan JChief Scientific OfficerSSale−1.55K$16.45−$25.5K−7.7%18.5K after
May 7, 2025 (view filing)May 25 daysLateMoore John RGeneral CounselSSale−1.93K$16.45−$31.7K−22.8%6.53K after
May 7, 2025 (view filing)May 25 daysLateKoch KevinPresident and CEOSSale−4.28K$16.45−$70.3K−17.2%20.6K after
May 7, 2025 (view filing)May 25 daysLateDonovan Joanne M.CMOSSale−5.19K$16.45−$85.3K−19.4%21.6K after
May 7, 2025 (view filing)May 25 daysLateDerakhshan BehradChief Business OfficerSSale−1.69K$16.45−$27.8K−7.7%20.4K after
May 7, 2025 (view filing)May 25 daysLateCarruthers R MichaelChief Financial OfficerSSale−1.31K$16.45−$21.6K−1.6%81.0K after
Apr 4, 2025 (view filing)7:33 PM ETApr 31 dayOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+496.8K$20.13+$10.0MNew position443.8K after2 lotsDuplicate filing
Apr 4, 2025 (view filing)Apr 31 dayThompson Peter A.Director, 10% OwnerPPurchase+496.8K$20.13+$10.0MNew position443.8K after2 lots
Mar 11, 2025 (view filing)4:33 PM ETMar 74 daysRussell Alan JChief Scientific OfficerSSale−200$30.02−$6.00K−1.3%14.9K after10b5-1
Mar 11, 2025 (view filing)4:32 PM ETMar 74 daysKoch KevinPresident and CEOSSale−100$30.00−$3.00K−0.7%14.5K after10b5-1
Feb 7, 2025 (view filing)4:38 PM ETFeb 5-62 daysRussell Alan JChief Scientific OfficerSSale−9.21K$30.04−$276.8K−38.3%14.9K after2 lots10b5-1
Feb 7, 2025 (view filing)4:38 PM ETFeb 5-62 daysKoch KevinPresident and CEOSSale−9.54K$30.13−$287.3K−39.7%14.5K after2 lots10b5-1
Feb 7, 2025 (view filing)Feb 52 daysDerakhshan BehradChief Business OfficerSSale−10.0K$30.03−$300.3K−37.3%16.8K after
Jan 30, 2025 (view filing)Jan 282 daysDonovan Joanne M.CMOSSale−25.0K$27.63−$690.8K−60.4%16.4K after10b5-1
Dec 31, 2024 (view filing)5:13 PM ETDec 301 dayRussell Alan JChief Scientific OfficerSSale−100.0K$27.37−$2.74M−87.1%14.9K after10b5-1
Dec 27, 2024 (view filing)Dec 243 daysSemigran MarcChief Development OfficerSSale−29.7K$29.68−$881.9K−81.6%6.72K after2 lots10b5-1
Sep 24, 2024 (view filing)8:25 PM ETSep 204 daysRussell Alan JChief Scientific OfficerSSale−75.0K$28.27−$2.12M−85.5%12.7K after2 lots
Sep 24, 2024 (view filing)Sep 20-234 daysMoore John RGeneral CounselSSale−70.9K$28.15−$2.00M−95.6%3.25K after2 lots
Sep 24, 2024 (view filing)Sep 204 daysDonovan Joanne M.CMOSSale−7.16K$28.29−$202.6K−33.0%14.5K after
Sep 24, 2024 (view filing)Sep 204 daysDerakhshan BehradChief Business OfficerSSale−42.1K$29.03−$1.22M−73.6%15.1K after
Sep 24, 2024 (view filing)Sep 204 daysCarruthers R MichaelChief Financial OfficerSSale−125.1K$28.57−$3.57M−94.8%6.90K after4 lots
May 3, 2024 (view filing)May 21 dayMoore John RGeneral CounselSSale−1.96K$18.91−$37.0K−37.6%3.25K after
May 3, 2024 (view filing)May 21 dayCarruthers R MichaelChief Financial OfficerSSale−2.16K$18.91−$40.8K−5.8%35.2K after
May 3, 2024 (view filing)May 21 dayDerakhshan BehradChief Business OfficerSSale−1.72K$18.91−$32.5K−11.3%13.4K after
May 3, 2024 (view filing)May 21 dayRussell Alan JChief Scientific OfficerSSale−1.58K$18.91−$29.8K−17.9%7.24K after
May 3, 2024 (view filing)May 21 dayDonovan Joanne M.CMOSSale−3.68K$18.91−$69.6K−15.6%19.9K after
May 3, 2024 (view filing)May 21 dayKoch KevinPresident and CEOSSale−3.15K$18.91−$59.6K−17.9%14.5K after
Feb 9, 2024 (view filing)Feb 7-92 daysMoore John RGeneral CounselSSale−29.8K$20.00−$596.8K−100.0%0 after3 lots10b5-1
Feb 9, 2024 (view filing)Feb 7-92 daysDerakhshan BehradChief Business OfficerSSale−10.0K$20.02−$200.2K−58.8%7.02K after3 lots10b5-1
Jan 25, 2024 (view filing)4:28 PM ETJan 232 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+454.5K$11.00+$5.00M+3.3%14.4M afterDuplicate filing
Jan 25, 2024 (view filing)Jan 232 daysCarruthers R MichaelChief Financial OfficerSSale−90.0K$15.78−$1.42M−75.6%29.0K after10b5-1
Jan 25, 2024 (view filing)Jan 232 daysThompson Peter A.Director, 10% OwnerPPurchase+454.5K$11.00+$5.00M+3.3%14.4M after
Dec 28, 2023 (view filing)Dec 262 daysFox Jonathan CDirectorPPurchase+10.9K$9.30+$101.0KNew position10.9K after
Dec 28, 2023 (view filing)Dec 271 dayMoore John RGeneral CounselSSale−8.50K$10.50−$89.2K−100.0%0 after